Circulating levels of uPA, and its receptor uPAR (urokinase-type plasminogen activator receptor), are significantly elevated in prostate cancer patients, and are higher in patients with lymph node and bone metastases, compared to those with non-metastatic disease [44,45]. Here, PLAU is linked to prostate cancer.